Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

Intech Investment Management LLC raised its position in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) by 41.1% during the fourth quarter, according to the company in its most recent 13F filing with ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Generali Asset Management SPA SGR has purchased 11,358 shares of Regeneron Pharmaceuticals, valued at approximately $8.1 million, during Q4. Institutional investors are actively trading the ...

Leerink notes that shares of Outperform-rated Sarepta (SRPT) are under pressure on the heels of the disclosure of a patient death following Elevidys treatment. While an “incredibly sad ...

Should Regeneron wish to compete, they will have to lower their prices, thereby eating into their profit margins. Interestingly, at the recent Leerink Global Healthcare Conference, the CFO Chris ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against other stocks that Jim Cramer discussed recently. Jim Cramer kicked off his latest ...

Leerink Partners analyst Geoff Porges maintained a Buy rating on Regeneron (NASDAQ:REGN) on Tuesday, setting a price target of ...

I think we'll get started. Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno ...

In a note sent to investors Tuesday, Leerink Partners analyst Daina Graybosch ... as 2seventy already divested its R&D assets to Regeneron and Novo Nordisk, and [Bristol Myers Squibb] manufactures ...